Aytu Biopharma (AYTU) Cash from Operations Growth (3y) (2015 - 2026)
Powered by 
Analysis
Aytu Biopharma (AYTU) Cash from Operations Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | 18.04% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 39.10% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | 18.31% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | 43.42% |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | -12.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -12.98% |
| Dec 31, 2025 | 51.81% |
| Sep 30, 2025 | 59.27% |
| Jun 30, 2025 | 33.79% |
| Mar 31, 2025 | 10.87% |
| Dec 31, 2024 | 32.56% |
| Sep 30, 2024 | 32.09% |
| Jun 30, 2024 | 49.99% |
| Dec 31, 2023 | 64.06% |
| Sep 30, 2023 | 70.23% |
| Jun 30, 2023 | 47.40% |
| Mar 31, 2023 | -28.88% |
| Dec 31, 2022 | 26.20% |
| Sep 30, 2022 | -45.21% |
| Jun 30, 2022 | -26.88% |
| Mar 31, 2022 | -40.16% |
| Dec 31, 2021 | -27.00% |
| Sep 30, 2021 | -11.46% |
| Jun 30, 2021 | -11.51% |
| Dec 31, 2020 | 2.13% |